Our white paper Healthcare in the post-pandemic world looks through key structural issues in the US healthcare system and solutions that will help build back a better and more resilient healthcare ecosystem.
- Medical technology companies have mobilised to set up critical infrastructures for diagnostic testing
- Biotech companies have made swift advances in therapeutics and vaccines to treat and prevent the viral infection
- Healthcare IT companies have rapidly scaled up virtual health platforms to enable the accelerated adoption of telehealth so that patients and clinicians can interact while observing social distancing rules.
- Beyond the healthcare sector, IT companies have improved the efficiency of contact tracing and offer the promise of early, pre-emptive detection of pandemics through AI algorithms.
The response to the pandemic is accelerating the transition to value-based rather than episode-based reimbursement systems. These should create incentives
- To close gaps in care, improve care coordination, reduce administrative waste, avoid overtreatment and prevent abuse and fraud
- To lower the cost of care
- To invest in improving the social determinants of health that include public education and health policies, the effects of social class, gender, ethnicity and income.
Healthcare in the post-pandemic world highlights the innovative, often disruptive, solutions that will help solve the inefficiencies and inequities that have been exposed.
Heathcare is also a BNPP AM Investigator theme
Any views expressed here are those of the author as of the date of publication, are based on available information, and are subject to change without notice. Individual portfolio management teams may hold different views and may take different investment decisions for different clients. This document does not constitute investment advice.
The value of investments and the income they generate may go down as well as up and it is possible that investors will not recover their initial outlay. Past performance is no guarantee for future returns.
Investing in emerging markets, or specialised or restricted sectors is likely to be subject to a higher-than-average volatility due to a high degree of concentration, greater uncertainty because less information is available, there is less liquidity or due to greater sensitivity to changes in market conditions (social, political and economic conditions).
Some emerging markets offer less security than the majority of international developed markets. For this reason, services for portfolio transactions, liquidation and conservation on behalf of funds invested in emerging markets may carry greater risk.